Study of IK-595 in RAS- or RAF-altered Advanced Tumors

NCT06270082 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

75

Enrollment

INDUSTRY

Sponsor class

Stopped Limited resources and strategic priorities

Conditions

Solid Tumor, Adult
Colorectal Cancer
Pancreatic Cancer
Malignant Melanoma
Ras (Kras or Nras) Gene Mutation
BRAF Gene Mutation
CRAF Gene Mutation
Non-Small Cell Lung Carcinoma
Thyroid Carcinoma
Gliomas, Malignant

Interventions

DRUG: IK-595

Sponsor

Ikena Oncology